These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24859340)

  • 1. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
    Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
    Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
    Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of genetic alterations in ameloblastomas relates to clinical features.
    Gültekin SE; Aziz R; Heydt C; Sengüven B; Zöller J; Safi AF; Kreppel M; Buettner R
    Virchows Arch; 2018 May; 472(5):807-814. PubMed ID: 29388014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report.
    Broudic-Guibert M; Blay JY; Vazquez L; Evrard A; Karanian M; Taïeb S; Hoog-Labouret N; Oukhatar CMA; Boustany-Grenier R; Arnaud A
    J Med Case Rep; 2019 Jul; 13(1):245. PubMed ID: 31340860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
    Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
    BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
    Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
    PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    Nguyen J; Saffari PS; Pollack AS; Vennam S; Gong X; West RB; Pollack JR
    J Dent Res; 2022 Nov; 101(12):1517-1525. PubMed ID: 35689405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Study of
    Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
    Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
    [No Abstract]   [Full Text] [Related]  

  • 14. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
    Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
    Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunohistochemical and genetic study of BRAF
    Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
    Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
    Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
    J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
    You Z; Liu SP; Du J; Wu YH; Zhang SZ
    J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
    Kumamoto H; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
    Oh KY
    Oral Oncol; 2023 Nov; 146():106585. PubMed ID: 37816291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.